Sanofi, GSK delay COVID-19 vaccine due to low response in elderly
France's Sanofi and Britain's GlaxoSmithKline (GSK) have said that their adjuvanted recombinant protein-based COVID-19 vaccine won't be ready until the last quarter of 2021. The vaccine's trial showed a "low immune response in older adults likely due to an insufficient concentration of the antigen", Sanofi added. The companies are planning to launch a Phase 2b study in February 2021.